Burden of Rare Genetic Variants Higher in Severe Schizophrenia
Individuals with severe, extremely treatment-resistant schizophrenia have an increased burden of high-impact rare genetic variants, according to a study published in the Dec. 21 issue...
December 14, 2021
by Drugs
Could Heavy Marijuana Use Be Driving Rise in Schizophrenia Cases?
There's been a sharp rise in schizophrenia cases linked with marijuana use since the mid-1990s, a new Danish study finds.
July 28, 2021
by drugs
Risk for Dementia Diagnosis Up for Seniors With Schizophrenia
Older adults with schizophrenia have an increased risk for receiving a diagnosis of dementia compared with those without serious mental illness (SMI), according to a study published in the June issue of JAMA Psychiatry.
June 25, 2021
by drugs
FDA approves Alkermes’ Lybalvi for schizophrenia treatment
The US Food and Drug Administration (FDA) has approved Alkermes’ Lybalvi as a treatment for adults with schizophrenia and for bipolar I disorder as maintenance monotherapy.
June 2, 2021
by pharmaceutical-technology
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
BioXcel today announced that FDA has accepted for filing NDA for BXCL501,orally dissolving thin film formulation of dexmedetomidine,for the acute treatment of agitation associated with schizophrenia and Bipolar disorders I and II
May 24, 2021
by drugs
Luvadaxistat Study Results Did Not Meet Primary Endpoint
Neurocrine Biosciences announced investigational drug luvadaxistat did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84.
March 8, 2021
by americanpharmaceuticalreview
Novel shows promise in Phase II schizophrenia trial
KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies.
February 26, 2021
by europeanpharmaceuticalreview
Ben-Gurion Researchers Develop Novel Method for Personalizing Clozapine Dose
Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel method for accurately monitoring blood levels of the antipsychotic drug, clozapine, using a blood drop from a finger prick.
February 19, 2021
by americanpharmaceuticalreview
Psychiatry Consortium funds project investigating new schizophrenia treatments
The international Psychiatry Consortium has funded its first project – a partnership which will investigate a new drug target for the treatment of schizophrenia.
January 26, 2021
by pharmatimes
New system could deliver schizophrenia medicine directly to brain
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.
January 20, 2021
by europeanpharmaceuticalreview
Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia
Teva Pharmaceuticals Industries and MedinCell announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM ...
January 13, 2021
by pharmaceutical-business-review
Neurelis Completes Pre-IND Meeting with FDA for Acute Agitation Treatment
Neurelis has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4. The FDA provided direction for the clinical development pathway for the investigational treatment.
December 9, 2020
by americanpharmaceuticalreview